{"id":903938,"date":"2025-11-03T06:31:48","date_gmt":"2025-11-03T11:31:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/"},"modified":"2025-11-03T06:31:48","modified_gmt":"2025-11-03T11:31:48","slug":"aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/","title":{"rendered":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025<\/b><\/p>\n<p>ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025.<\/p>\n<p>\nAurinia\u2019s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3DmNAFNJFu&amp;esheet=54349911&amp;newsitemid=20251103166461&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=2fcbb3397ec11ceb31179c1b4e261c07\">here<\/a>. To join the conference call, please dial 877-407-9170 \/ +1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website.<\/p>\n<p><b>About Aurinia<\/b><\/p>\n<p>\nAurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS<sup>\u00ae<\/sup> (voclosporin), the first FDA\u2011approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251103166461\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251103166461\/en\/<\/a><\/span><\/p>\n<p><b>General Investor Inquiries:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@auriniapharma.com\"><b>ir@auriniapharma.com<\/b><\/a><\/p>\n<p><b>KEYWORDS:<\/b> Maryland United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health FDA Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251103166461\/en\/2629304\/3\/AUPH_logo_Registered.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia\u2019s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 \/ +1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-903938","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia\u2019s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 \/ +1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia is &hellip; Continue reading &quot;Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T11:31:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025\",\"datePublished\":\"2025-11-03T11:31:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/\"},\"wordCount\":241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/\",\"name\":\"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-11-03T11:31:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/","og_locale":"en_US","og_type":"article","og_title":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk","og_description":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia\u2019s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 \/ +1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia is &hellip; Continue reading \"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T11:31:48+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025","datePublished":"2025-11-03T11:31:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/"},"wordCount":241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/","name":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-11-03T11:31:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251103166461r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/903938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=903938"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/903938\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=903938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=903938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=903938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}